Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Classical antineoplastic therapies present known systemic adverse reactions.
• Novel anticancer agents, including epidermal growth factor receptor inhibitors, offer improved outcomes but introduce unique, less-understood side effects.
• Cutaneous adverse events, such as hand-foot syndrome and acneiform eruptions, are common with newer targeted therapies and can be severe.

Purpose of the Study:

• To review the specific cutaneous adverse effects associated with novel anticancer treatments.
• To highlight the importance of managing these side effects for treatment adherence and patient survival.
• To explore the potential prognostic value of certain skin reactions.

Main Methods:

• Literature review of adverse reactions from epidermal growth factor receptor inhibitors.
• Analysis of reported cutaneous side effects and their management strategies.
• Correlation of skin adverse events with treatment response and survival data.

Main Results:

• New anticancer drugs frequently cause specific skin toxicities (hand foot syndrome, acneiform reactions).
• These side effects can be severe, necessitating dose adjustments or treatment cessation.
• Close collaboration between oncologists and dermatologists is vital for effective prevention and management.
• Certain cutaneous adverse events may indicate a positive prognosis for cancer treatment response and overall survival.

Conclusions:

• Management of novel anticancer drug-induced skin toxicities requires multidisciplinary input.
• Proactive dermatological intervention can mitigate severity and improve patient outcomes.
• Skin adverse events may serve as predictive biomarkers for therapeutic efficacy.